| pubmed-article:12100957 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:12100957 | lifeskim:mentions | umls-concept:C0027651 | lld:lifeskim |
| pubmed-article:12100957 | lifeskim:mentions | umls-concept:C0034493 | lld:lifeskim |
| pubmed-article:12100957 | lifeskim:mentions | umls-concept:C0022646 | lld:lifeskim |
| pubmed-article:12100957 | lifeskim:mentions | umls-concept:C0038952 | lld:lifeskim |
| pubmed-article:12100957 | lifeskim:mentions | umls-concept:C0021102 | lld:lifeskim |
| pubmed-article:12100957 | lifeskim:mentions | umls-concept:C0031928 | lld:lifeskim |
| pubmed-article:12100957 | lifeskim:mentions | umls-concept:C0850292 | lld:lifeskim |
| pubmed-article:12100957 | pubmed:issue | 1 | lld:pubmed |
| pubmed-article:12100957 | pubmed:dateCreated | 2002-7-8 | lld:pubmed |
| pubmed-article:12100957 | pubmed:abstractText | The increased incidental detection of small (less than 4 cm) renal tumors has stimulated investigations of minimally invasive therapies. Radiofrequency energy is a relatively new and evolving technology that has been used for a variety of experimental and clinical applications. We evaluate the efficacy of hypertonic interstitial saline-augmented radiofrequency therapy to ablate a malignant VX-2 tumor implanted in a rabbit kidney, as measured by the completeness of tumor destruction and progression to metastasis. | lld:pubmed |
| pubmed-article:12100957 | pubmed:language | eng | lld:pubmed |
| pubmed-article:12100957 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12100957 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:12100957 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12100957 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:12100957 | pubmed:month | Jul | lld:pubmed |
| pubmed-article:12100957 | pubmed:issn | 1527-9995 | lld:pubmed |
| pubmed-article:12100957 | pubmed:author | pubmed-author:MunverRaviR | lld:pubmed |
| pubmed-article:12100957 | pubmed:author | pubmed-author:DelvecchioFer... | lld:pubmed |
| pubmed-article:12100957 | pubmed:author | pubmed-author:PremingerGlen... | lld:pubmed |
| pubmed-article:12100957 | pubmed:author | pubmed-author:PolascikThoma... | lld:pubmed |
| pubmed-article:12100957 | pubmed:author | pubmed-author:ThreattChris... | lld:pubmed |
| pubmed-article:12100957 | pubmed:issnType | Electronic | lld:pubmed |
| pubmed-article:12100957 | pubmed:volume | 60 | lld:pubmed |
| pubmed-article:12100957 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:12100957 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:12100957 | pubmed:pagination | 170-5 | lld:pubmed |
| pubmed-article:12100957 | pubmed:dateRevised | 2006-11-15 | lld:pubmed |
| pubmed-article:12100957 | pubmed:meshHeading | pubmed-meshheading:12100957... | lld:pubmed |
| pubmed-article:12100957 | pubmed:meshHeading | pubmed-meshheading:12100957... | lld:pubmed |
| pubmed-article:12100957 | pubmed:meshHeading | pubmed-meshheading:12100957... | lld:pubmed |
| pubmed-article:12100957 | pubmed:meshHeading | pubmed-meshheading:12100957... | lld:pubmed |
| pubmed-article:12100957 | pubmed:meshHeading | pubmed-meshheading:12100957... | lld:pubmed |
| pubmed-article:12100957 | pubmed:meshHeading | pubmed-meshheading:12100957... | lld:pubmed |
| pubmed-article:12100957 | pubmed:meshHeading | pubmed-meshheading:12100957... | lld:pubmed |
| pubmed-article:12100957 | pubmed:meshHeading | pubmed-meshheading:12100957... | lld:pubmed |
| pubmed-article:12100957 | pubmed:meshHeading | pubmed-meshheading:12100957... | lld:pubmed |
| pubmed-article:12100957 | pubmed:meshHeading | pubmed-meshheading:12100957... | lld:pubmed |
| pubmed-article:12100957 | pubmed:meshHeading | pubmed-meshheading:12100957... | lld:pubmed |
| pubmed-article:12100957 | pubmed:meshHeading | pubmed-meshheading:12100957... | lld:pubmed |
| pubmed-article:12100957 | pubmed:meshHeading | pubmed-meshheading:12100957... | lld:pubmed |
| pubmed-article:12100957 | pubmed:meshHeading | pubmed-meshheading:12100957... | lld:pubmed |
| pubmed-article:12100957 | pubmed:year | 2002 | lld:pubmed |
| pubmed-article:12100957 | pubmed:articleTitle | Hypertonic saline-augmented radiofrequency ablation of the VX-2 tumor implanted in the rabbit kidney: a short-term survival pilot study. | lld:pubmed |
| pubmed-article:12100957 | pubmed:affiliation | Division of Urology, Department of Surgery, Duke University Medical Center, Durham, North Carolina 27710, USA. | lld:pubmed |
| pubmed-article:12100957 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:12100957 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:12100957 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:12100957 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:12100957 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:12100957 | lld:pubmed |
